Multiple sclerosis in Northern Ireland: a historical and global perspective. by McDonnell, G. V. & Hawkins, S. A.
The Ulster Medical Journal, Volume 69, No. 2, pp. 97-105, November 2000.
Multiple Sclerosis in Northern Ireland:
A historical and global perspective
G V McDonnell, S A Hawkins
Accepted 27 September 2000
SUMMARY
The uneven worldwide distribution ofmultiple sclerosis has been ofinterest to epidemiologists,
neurologists andstatisticiansforoveracentury,prevalence ratesforthediseaseapparentlybeing
determined byvariationsinage,gender,geography, raceandethnicgroup.NorthernIrelandhas
been recognised as an area of high MS prevalence since the truly seminal work of Allison and
Millar almost 50 years ago.
ThemostrecentstudyinNorthernIrelandwasundertakenin1996andinvolvedtheneighbouring
districts of Coleraine, Ballymena, Ballymoney and Moyle (population, 151,000). Overall, 254
definite and probable cases were identified (prevalence: 168.2/100,000) with a further 34
suspected cases (overallprevalence: 190.7/100,000). Femalespredominated (ratio,2.1: 1) andthe
average age at onset was 31.6 years. The highest age specific prevalence rate for females was in
the 35-44 years old age group (519.6/100,000) and for males was in those aged 55-64 (292.3/
100,000). The spectrum ofdisability was broad and 20% could be considered to have relatively
"benign" disease. These figures sadly confirm that Northern Ireland has one ofthe highest and
rising MS prevalence rates in the world and implies an enormous potential for societary costs.
MS EPIDEMIOLOGY - THE EARLY YEARS
Accumulated data over the last century indicates
that multiple sclerosis (MS) is the commonest
disabling neurological disease ofyoung adults in
developed countries. Although the earliest
attemptstoestablishthefrequencyofMSinvolved
the observation of the numbers of cases among
hospital admissions with nervous diseases, in
1922 the study of the disease was taken a stage
further by the reported distribution ofMS in the
United States based on diagnoses among army
inductees in World War i.1
The first attempt to establish properly MS
prevalence by identifying the total number of
cases within adefinedpopulation was performed
in Switzerland in 1918-22 and reported in 1926
(prevalence: 36.4/100,000).2 Thefirst such study
inthe BritishIsles was undertaken by aneminent
Belfast neurologist, Sidney Allison, in Wales in
1929 (prevalence: 25.8/100,000).3
Although several hundred epidemiological
surveys ofMS have been undertaken worldwide,
the credit for the first recognition that MS
exhibited an uneven distribution must go to
Charcot, who in 1868 commented that "even
today Idonotbelieve thatdisseminated sclerosis
is known in England" and in 1877 continued to
observe that although the disease was prevalent
inFrance, itwas littlerecognisedinGermany and
uncommon in England.4'5 Although these
observations are inapplicable today, other
variations are now well established.
EVIDENCE FOR A LATITUDINAL GRADIENT?
The theory that the epidemiology ofMS shows a
latitudinal gradient in frequency probably
originates from the demonstration in 1950 that
MS death rates increased from south to north
within North America.6 Subsequent studies
gradually developed the picture of a higher
prevalence in temperate than in subtropical and
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tropical zones, with a suggestion of a decline in
rates again towards the poles. Some ofthe most
elegant supportive studies have come from
Australia,wheretheprevalencedeclinesgradually
from tropical Queensland (12/100,000) in the
north to Tasmania (76/100,000) in the south.7'8
Furtherevidenceforgeographicorenvironmental
factorsinfluencingthefrequencyofMShascome
from migration studies. In South Africa, MS
prevalence in immigrants from the UK and other
European countries is about 36/100,000
population.9 This rate is intermediate between
those for the countries from which these people
originated (50-100/100,000) and that for native
born white South Africans (11/100,000). Further
studyofEuropeans migrating toSouthAfricahas
also indicatedthatthe riskofMS is relatedto the
age ofmigration.10 Inthe group migrating before
age 15, the number developing the disease was
only one-thirdofthenumberexpectedfromrates
in the European population generally.
The effects of latitude and changes in risk with
migration are however only part of the picture.
For example, in the US the significantly higher
MS prevalence in the northern states has been
shown to be better correlated with the extent of
Scandinavian ancestry.11 What is now clear is
that what have previously been interpreted as
geographicalorenvironmentalfactorsinfluencing
disease prevalence are more likely to be racial
and genetic. Generally, MS is most frequent in
areas settled by individuals of predominantly
Scandinavian descent.
CLUSTERS AND EPIDEMICS
Within these apparent trends along latitudinal
gradients and across ethnic groups, the
identification ofapparent clusters andepidemics
in, forexample, theFaroes,12Iceland,'3 Florida,"4
Norway,15andDenmark16hascausedmuchintense
speculation regarding more specific possible
aetiological factors, in particular, infectious
agents. To date, despite intensive survey, no
single infectious agent has been successfully
incriminated.
POST-WAR SURVEYS IN GREAT BRITAIN
SinceWorldWarIItherehavebeenmorethan 30
epidemiological surveys in Great Britain (GB).
Themostintensivelysurveyedareasuntilrecently
havebeenthenorth-east ofScotland, Orkney and
Shetland. Studies have involved numerators and
denominatorsbothlargeandsmall,useddiffering
diagnostic criteria and employed varied
epidemiological methods.
The Orkneys and Shetland have had the highest
prevalence rates forMS in the world, prevalence
in the former reaching a peak of 309/100,000 in
1974.17Interestingly, andincontrasttothepattern
of earlier studies on these islands, both island
groups have demonstrated a decline in MS
prevalence in their most recent studies.18"9 On
the Scottish mainland, three studies have been
conducted in the north-east, largely based on
Grampian, the prevalence there reaching a peak
of 178/100,000 in 1980.20
Such figures in Scotland, together with a
perceptionthatMS wasmuchless commoninthe
south of England, contributed to a belief that a
north-south gradient forMS prevalence exists in
GB. Over the past decade however there have
been several well conducted studies in England
andWaleswhichhavechallengedthishypothesis,
withbroadly similarprevalencerates forareas as
far apart as Jersey (113/100,000),21 Sussex (136/
100,000),22 North Cambridgeshire (118/
100,000),23 Glamorgan (120/100,000)24 and
Rochdale (122/100,000).25 The absence of a
latitudinal gradient within Scotland itself has
also been confirmed by studies in south-east
Scotland(prevalence: 187/100,000)26andTayside
(prevalence: 184/100,000)27 which have found
prevalence rates similar to those for Grampian,
Shetland and Orkney.
THE HISTORY OF MS EPIDEMIOLOGY IN
IRELAND
Northern Ireland has one of the most surveyed
populations forMS intheworld,previous studies
havingbeenundertakenin 1951, 1961 and 1987.28
30The original studies ofAllison andMillarwere
among the mostextensive evercompleted, based
as they were on thepopulation ofthe province as
a whole. They identified Northern Ireland as a
highriskareaforMS, observingprevalence rates
of 51/100,000 in 1951 (population: 1,370,709)
and 80 per 100,000 in 1961 (population:
1,484,775). Morerecently in 1987, a study ofthe
contiguous Coleraine, Ballymoney and Moyle
districts in the north-east of Northern Ireland
(population: 86,500)producedacrudeprevalence
rate of 138/100,000.30
The 1951 study provided a template for all
subsequent studies. All hospitals and doctors in
the country were surveyed. A scheme of
C The Ulster Medical Society, 2000.Multiple Sclerosis in Northern Ireland 99
classifying patients was established whichis still
widely applied. For this purpose patients were
categorised as having "probable MS" (some
physical disablement, usually aremitting quality
in the history and on examination, physical signs
explicable only by multiple lesions), "early MS"
(patients showing few or no physical signs but
having arecenthistory ofremitting symptoms of
the kind commonly associated with the onset of
thedisease)or"possibleMS"(suggestiveclinical
findings but a progressive or static history and
insufficient evidence of multiple lesions).
Remarkably, all 887 cases on the provisional
register were individually assessed by Allison
andMillar, the diagnosis being discarded in over
20%.Painswerealsotakentoestablishanaccurate
incidence rate by personal questioning and
checkingstatementswithdoctors,hospitalrecords
and relatives. The final overall incidence figure
was 2.74/100,000. Allison and Millar's huge
efforts were howeverunderminedby atleasttwo
factors. Firstly, by the prevalence date replies
hadnotbeenreceivedfrom25% ofthe doctors in
Northern Ireland. Secondly, the incidence rate
was calculated overaprolongedperiod andup to
the prevalence date (1937-51) and may therefore
have missed patients who had onset of disease
during thisperiodbutwhodiedbeforethe survey
was carried out, and also those who had onset
duringthisperiodbuthadnotyetbeenidentified.
Oneconclusionofthestudyalsoappears suspect.
Although the authors state that there was no
evidencetosuggestthatthediseasewasunevenly
distributed, there is a considerable variation in
prevalence rates across the region from 24/
100,000inCo.Londonderryto63/100,000inCo.
Tyrone.
In the second study by Allison and Millar, 1,146
caseswereidentifiedinapopulationof1,425,000.
Again all of these patients were individually
assessed. An unusually high proportion of
"possible" cases were noted -29% -rather more
than the already high level seen in 1951 - 21%.
However, even allowing for this increased
recognition of "possible MS", the confidence
limits for the 1961 prevalence figure (76-85/
100,000) lie well above those from 1951 (47-55/
100,000).
The 1987 study was the first in Northern Ireland
to use the Poser criteria.31 It was also the first to
use the Kurtzke disability status scale 32 as a
measure of neurological impairment in an MS
population. The prevalence rate for probable
disease by the Allison and Millar criteria was
104/100,000 andfordefinite/probablediseaseby
Poser was 97/100,000.
Studies of MS prevalence elsewhere in Ireland
have been less detailed, although one study
reported in 1977 involved the whole population
of the Republic of Ireland.33 Covering almost
threemillionpeople,itwassubjecttotheproblems
of accurate case ascertainment inherent in a
population of this size. Although many sources
were used to identify cases and the existence of
the study was advertised in the medical press, no
data is provided by the authors on response rates
to requests for information. Also patients who
were identified to the researchers were not
individuallyassessed,theopinionoftheattending
neurologist or physician being accepted. No
diagnostic criteria were used, patients being
designated as either probable or possible cases,
and no measure of disability was applied. The
overallprevalencerateforpatientswithprobable
or possible disease was 73/100,000. In a further
study in the county of Wexford in 1984,34 the
criteria of McDonald and Halliday were used
which make comparison with other surveys
difficult. Although all patients were individually
assessed, a remarkable 40% of this population
were deemed to have benign disease, suggesting
a bias in the case ascertainment against those
with greater disability. It is also noteworthy that
the quoted prevalence rate of 48.4/100,000 for
clinically definite and progressive probable MS
was actually less than that identified for the
county 13 years earlier (54.5/100,000).33
CURRENT SITUATION IN NORTHERN IRELAND
In 1998 we first reported on a furtherprevalence
study in Northern Ireland.3" Our aims were to
update the MS prevalence in the new era of
magnetic resonance imaging and more
sophisticated immunological investigation. A
further purpose was to provide a database for
immunological andgenetic studies forwhichthe
relatively homogeneous conformation of this
population is ideal.
METHODS
The survey populations were the neighbouring
Ballymena, Coleraine, Ballymoney and Moyle
districts, spanning the counties of Antrim and
Deify. The total land area of 2,030km2 lies
between latitudes 5407 N and5503 N. Inthe 1991
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census, the population was 146,066, but by mid-
year 1995 it had risen to an estimated 151,000 -
Ballymena (57,500), Coleraine (54,100),
Ballymoney (24,600), Moyle (14,800).
Primary sources for case identification were the
records of the Northern Ireland Regional
NeurologyService(NIRNS) attheRoyalVictoria
and City hospitals in Belfast and those held in
outreachneurologyclinics servingthestudy area
at the Coleraine, Waveney, Moyle, Antrim and
Mid-Ulster hospitals. Hospitals with inpatient
diagnostic indices and computerised databases
were further sources.
ApostalsurveyofGPsintheareawasperformed.
Those failing to respond were canvassed on a
second and third occasion where necessary.
Local branches ofthe Multiple Sclerosis Society
of Northern Ireland at Ballymena, Coleraine,
Ballymoney, AntrimandLamewereapproached
for information. Another charity, Action MS,
was also approached. The records of the MS
Centre at the Dalriada Hospital in Ballycastle
which provides a respite care facility were
examined.
The hospital and/or GP records of all patients
identified were studied. Potential MS patients
were then invited for assessment. An invitation
wasnotissuediffeltbytheGPtobeinappropriate.
Assessments occurred at a neurology clinic, in
thepatient's localhealth centre orownhome and
involved interview regarding date of onset, date
of diagnosis, nature of the initial episode,
subsequent clinical course and family history.
Date of onset was obtained from the patient
where possible, from the medical records if not.
Date ofdiagnosis was obtainedfromthe medical
records.
Those satisfying the Poser criteria for clinically
definite (CDMS), laboratory-supported definite
(LSDMS), clinically probable (CPMS) or
laboratory-supportedprobable(LSPMS)MSwere
acceptedasprevalentcases.Toenablecomparison
with previous studies a "suspected" group was
included and the criteria of Allison and Millar
were also employed.
A comparison of this study with the previous
three in Northern Ireland was performed using
the Allison and Millar criteria and calculating
confidence intervals by a standard method.36
Patients were categorised as having relapsing-
remitting (RRMS), secondary progressive
(SPMS) or primary progressive (PPMS) MS.
Those with an EDSS of <3.0, .10 years after
onset were considered to have benign MS.
Patients were deemed prevalent if alive and
resident in the study area on July 1st 1996.
Addresses of patients were established as being
within the study area using postcodes and maps
obtained from HMSO and Ordnance Survey.
Ethical approval was obtained from the Queen's
UniversityofBelfastResearchEthicsCommittee.
RESULTS
TheprovisionallistofpeoplewithMS comprised
402 names. Many were identified by more than
onesource.Ninety-fourof97(96.9%)GPswithin
the area responded positively to requests for
information. Sources for the provisional cases
andtheproportion ofthe overallnumbernotified
were: GPs, 247 (61.4%); departmental records,
NIRNS, 217 (54.0%);MScharities, 109(27.1%);
hospital database inpatient codings, 89 (22.1%);
Dalriada MS Centre, 38 (9.5%).
Patients were excluded from the provisional
register on the following grounds: residency
outside the study area (47 cases); deceased (45
cases); notMS (22cases). Therefore288patients
remained alive and prevalent within the study
areaon 1stJuly 1996. Thesources forthesewere:
GPs,230(79.9%); departmentalrecords,NIRNS,
158 (54.9%); MS charities, 74 (25.7%); hospital
database inpatientcodings, 69 (24.0%); Dalriada
MS Centre, 33 (11.5%). Of the 288 prevalent
patients, 116 (40.3%) were notified by a single
source: GPs, 85 (29.5%); departmental records,
NIRNS, 19 (6.6%); hospital database inpatient
codings, 10 (3.5%); MS charities, 1 (0.3%);
Dalriada MS Centre, 1 (0.3%).
Two hundred and fifty-one of the 288 patients
(87.2%)wereformallyinterviewedandexamined.
In a further eight cases (2.8%) an EDSS was
calculated using information provided by the
general practitioner or by other consultant
neurologists during clinic attendance. The
diagnostic classification ofprevalent casesusing
the Poser criteria was as follows: CDMS - 185
(64.2%); LSDMS - 24 (8.3%); CPMS - 43
(14.9%); LSPMS -2 (0.7%), and; suspected -34
(11 .8%). ApplyingtheAllisonandMillarcriteria
the classification was: probable MS - 186
(64.6%o); early probable and latent MS - 60
(20.8%), and; possible -42 (14.6%o).
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The prevalence rate based on all 288 patients is
190.7/100,000 (95% CI 168.7-212.7/100,000)
whilstrestrictingtothosewithdefiniteorprobable
diseasebythePosercriteriagives aprevalenceof
168.2/100,000 (95% CI 147.5-188.9/100,000).
ThepreviouslyunsurveyedBallymenapopulation
contained 110 patients [prevalence: 191.3/
100,000 (95% CI 155.6-227.0/100,000)], 100
fulfillingthePosercriteriafordefiniteorprobable
disease [prevalence: 173.9/100,000 (95% CI
139.9-208.0/100,000)].
There were 196 female and 92 male patients
(ratio 2.1: 1). The mean age ofprevalentpatients
was 49.3 (range 18-79, SD 13.3) years, the mean
age for females and males being 48.3 (SD 13.4)
and 51.5 (SD 13.0) years respectively. Mean age
of onset was 31.6 (range 12-66, SD 10.1) years,
the figures forfemales and males being 31.0 (SD
10.1) and 33.0 (SD 10.1) respectively. The age
and sex specific prevalence rates are given in
(Table 1). Both the peak age specific prevalence
rate and modal age ofprevalent female cases are
in the 35-44 year age group. For males the peak
prevalence rates are in the 45-54 and 55-64 year
age groups whilst the modal age group for
prevalent males is 45-54 years.
The homogeneity and stability ofthe population
is emphasised by 90.9% of those with definite/
probable disease being born either within the
studyarea(184patients)orelsewhereinNorthern
Ireland (47 patients). This figure reaches 95.1%
upon exclusion of those cases whose place of
birth was not ascertained, with just nine cases
(3.5%) born elsewhere in the British Isles and
three (1.2%) born overseas.
In those with definite or probable disease the
mean interval between initial symptoms and
diagnosis was 6.2 years. The mean duration of
diseaseindefinite/probablecaseswas 18.4(range
0-52, SD 11.4) years. Using the technique of
doubling the mean duration at prevalence day,
the mean life expectancy was 36.8 years.37
ThedistributionofKurtzkeEDSS scoresisshown
in the figure. The mean EDSS score was 4.9 and
the median 5.5. Clinical course from onset was
establishedin280(97.2%)patients. Ninety-eight
patients (35.0%) had RRMS, 36 (12.9%) had RR
and benign disease, 111 (39.6%) had SPMS and
35(12.5%)hadPPMS.Of180patientsundergoing
anEDSS assessmentandhavingdiseaseduration
of .10 years, 36 (20%) had a benign course.
Initial symptoms were established in 283 cases
(98.3%). The commonest was sensory [95
(33.6%)] followed by motor [78 (27.6%)],
brainstem/cerebellar [70 (24.7%)] and optic
neuritis [57 (20.1%)]. Twenty-six (9.2%) had
more than one of these symptoms initially and
nine (3.2%) had another form of disturbance at
TABLE I
Prevalence ofdefinite/probable MS in Coleraine, Ballymena, Ballymoney and Moyle per 100,000
by age and sex.
Age Group Male Female Total
(years No. Rate/l05 No. Rate/l05 No. Rate/l05
0-14 0 0 0 0 0 0
15-24 0 0 5 41.3 5 20.3
25-34 8 74.9 20 186.3 28 130.8
35-44 13 132.9 50 519.6 63 324.6
45-54 24 286.9 42 482.3 66 386.6
55-64 19 292.3 32 443.0 51 371.6
65-74 11 212.4 25 394.6 36 312.7
75+ 2 68.3 3 56.0 5 60.4
TOTAL 77 104.1 177 229.9 254 168.2
O The Ulster Medical Society, 2000.102
50 ::::.::::.,:,:::::::.:::::::::::::::::::::::::::,::::,::::.::.:::::::::::::,:,::..::::::::::::::::.,:::::::.:;::: ::::::::,..,::::,::::::::::::.::::::::::,:::::::.:::.,:::::::::..::..,:,:::::::::::::.:::.,.::::,:::::.: ........... ::::::::; ............:::.:::::::::':::.,:::::::.............." :::::::::::::.:.,.,::
.::: "' .::: ::.:..::::::-;:::::::;::::::::.:::.:.::::::,:::::::.,:::::::..,:::::::::::. ...:.::..:::::::::::::::.,::::.::::::...::;:::::: .:. ::::. .::::. -:::::::-.:,::,::::,:::::::
:::.::.,:,:.,:.:::::: ::.::::" :.,.,:::::::::.:::::.,:,::::::::. ....:." ::,:.,,:::::: .................:::::::.:::::::::.,::::::::.:::.::::::"::::::::.,::,:,::::::::::.::
:::::::::.,::.,.,::,:::,::::::::: ....................... ::::::::::::.,:::.,::.,::::: .:::::: ........Z.... I'll ..... ::::::... .:::::::::.::.::::,:.,.,.,.:." :.,:::::,.::::.:::::" :::::: .................... ::::. .:::::::.:...................... :::.
I::::::::.;.;:.I:::::::::: ..................... ::,..::
::.,.,:::::::::::::.:."::::::::,:..::.,:::::::::::..::::::::::::::::::::;::::::::::-.::-.:::.-:.-:-:::::-.::-.:::::::.-.-:
...............
.:t:.:::::::::::'::.,::::::::,:::::::::,:.-::::::::: ....................:.:.::::::::::::,..:::":::.,::::,::::.::..::::: :::::I
.......... :::::::::::. .: :::,:::::::::::::::::::::::::::.:::.:::::::::; ...........
-.
.::::::::"-,:.":".::::" :,.:: .......................................... :.::.::,:
..... :.,.,:,:::::::::::,:::::.",:::::::::..:.::::.,::::::::::,::.,::::.,::::::::::::::.:.,::::.,:::::::::,.:::.,::.,::.::::::::. .::::::::::::::::::::::::::::::::::.
.::::..:.:-:.-.-: .................. :: :.:::::::::::::.:::::::::::::,::::::.:::..::::::,::.::::,::::.,::...........................I...........: .:::::::.,." ::::::"","":::::: :::.: ............ .:::::. .:::,:::::::::::::.,::::::::::::::::.,:.::::::
.:::. ::. :..... ::::,.:::::::::,: .:::: .:. .............::: ::::::.,::::::::::::::.,::,:::::::::;:::::::,.,:::::::::::::,::".,::.l:::::::::::..::..,.:;::,:::::,.:.:..:::.,:.,:, .:..::
.................... :::. .:.:.. .---::::::::::::::.:::::.-.-::.-:::
...I........:::::... .:::. :.":::.,::::::.:"::.::,::.,::::::::::.:::" "," ::::::.:::::: ::I::::!:::::,::::::
:.,:::,:::: .::.::::.::::.-.::..:::.,::::: ::::::::::..::::. ::.:::::::::::::::::::::::::::::::::::::::..:::.,:::::::::;:::.,.,::::::::,::. .:. ,:::, ,:::, I.:::::::::::::::,...:::.,:::::::::, ::::::::::::::..::::...:::::::::::..:........::.::::::::.:::..:..:::::::::::::::::::..:::::::::::::-.-.-.:..:::::::::::::; ::.:..:::::::::.:..::.....::::::::::::.:;::,.,:
::::::::::::..::..:::::::::::;..; ..........................................................................I................ ......:. :.:::: ............I.......................
40 ....m....................................... ,:::::::::::.:.::;::::::.-:::::: :.:.:::::::::::::: :.-.-:::::::::::.:::.-:::.-::::::::::.:-....-: ........................s :.::.::.:::. .:: -::::d :::::::::.;.::::::
::::::::: :11 ::::::: ::::
.:::::,::,:::::::::,: ::::::::: 1.!:: ::11: :::, I:::::.:::. .....:..... ::.. :::::::::: ::.:: :: ::::::::: :...:: ::::: I:::::. ::.: I:::..:.:: ::.:::::::::::. ::..: ..::::: .! :: ..
.;: :::::::::::. ::.1
I.;::::..,:, .::.:::::::::.:. .::.: ::::,:::. .:::::, :::,:. .. :.. :::::.,:: :.;:.
I.::.::...,: :::.!::::.:..,:::. :::..:::..:.. ..::::: :1.1.1 ..,::-1.1::::::N:.::.:. .:.,.,.,::.,::," :::: ::::: :: ::::::.:"
.:::.::: ::::::.:.: .::d:::::.::::::.::.,:: ::::::. .::::: ::,::::: :.:.;:.11: ::I I:;
::::..::::..::::::: :--:.-:-:::::::.:.::::d..:::: .::::.:.::-.:,., ;::::::,
.I..:. :::::d:::.::::.1 :::,:. .:::::::::::: :::::... :::::::.::::::d:.:, :::::: :;
.::::: ..:::::::::.:.::::-::::d:::::::::.:.:;.-:::- .:: .........................................d.................. 35 .......d ......... :::.-:::II.:::,.;:..IIII ,::::.,:,:::::::.::::.,:,::.,::::: :::::: :....,:.,:, ::,::::::, ::: :::::,::.::: ::. .:: :. .:. .::::: 2 .1::::::::: .::::::::::: ":.:::::: :: :::: :::::: ..::: I:::, :::::::.::: :.,.,.,,:::::, :::: ::: ,::::: I:::::,
:::::::..:::::.1 :::::::
:::::::::..::::::::::::: :: I. :::d:::::.:...: ::: :: ::::. .::::: :::::..:::::::.: ::.:: :::::, ::::: ":::::::::,::: ::::::. :. ,:.;: :: I:::::: :.:,.,..::::: :::: .1:.1 :::::::.
:::...:::::,::::. .:::::. .:::.::. .1.1: ::::::::,.:.:::: :::.::.::::::" :::::::::::.: :: :::::::::.: ..:.:..:. ,:.,:: :::::::: I:::::::I:::: ::.:.:::I I:.: ::. .;:: .::::: :::: ::
:::::::::,. ,:..
I::Id:. .1::: ::::::, ::;.:::. ... ..::::
.::::..:.:::::::::: ::,:::::...... .::. ::::::::::::::::.::
.::::::::::. ;:..:: ::::: :::::::::, :::: :::::: g 30 ::::::, ::::,: :.:::::::::
.1:::::::::::, ::::::; ;.1 :::d::: .:: :::: :::::::.
IIIdl::::::::::.:::: :::::,::: :.1 :::d::::1:1 :;.;:: I:::::
.:::::::..::::. .:::::::: .:: ::..: :: :.I. ::::" ::::::.., ::::. ::.::..::: :;::::::: ::.,: ::,: ::::,: ...." ::::
::::. .:::::::::: :::::::::: :::::.1 :: ::.1 ::::::::: :11: :.:,::.1 .::.::: ::.: ::::::.:. ;.:: .1::::: d:::, :.::::::::: :.::::::::::::: :::: .::. .:: ::::::::::
.:::::;..::..: :::. ::::.:::: .:.., .1::::, :::: .,.'..::,..::: :::,:::;:: .: I: :::::::1:1 ::::: I.1 :.:::::.:,.: :::::::::::: :::: N :..:,
:::::::::.:,:::::::::::: ::..:::::::: I:::::::::: :.
:::N ,::: .1 .1 ::::::: :.1 :::::: .::::::. .d..:::::::
..::::: :d::. ::: ::::::.:::::.::.:: ::: :.. ::d::: ;:.:: ::.. :::::: :-. :::::: :::::: ::: -. -,
i. .:::::. ..:::.::::.:::.::.:: -
mmmoaamm;oomm ..;;;;;;;;;;;; ....I...
...............................
;:::::: :.,:::: ::::: :::::., ::.1 .1::.:::: ..::: .1:. .:: ... .:::
%" ::::.:: :: :::::: :;.::: .::.. :::::. ::. .:.: .:..: :::::: ::::: :::::::::: :: ::::::::.::::::::
:::: d:::::;:::...,::::.I::: ,:::::::.:.., ,:::::::: ,::
I.::::::,:::::::::::::::::::: ...................d:.::.-.:.-.:::,:,:::::, .......
::.-::::::::::::::::: .:.::.::::.,.,::::::::..::..",::.,.,.,:::::;.: :::::,::
:::::::.
1.1::: ,:::::::::: .:.
.::.
- .:::::::..,::-::::::I..::::.,:::::::::.:.: ::::::::::
.::::::::..::::::::.-.-.I.I::: ,:::: la :::. .,:::..:::::. :::::::::::. .:: ,:: ,:::::::::.,::::: 1.1:.I::::::::::.:::::::::::::: :::.::::::..::::::::,.::,::::::: .::::.:: ::: I.......- ....d.......I....................... 20
,:::.:.::..,.,::.,: I.::::: I.:::..:::.,:: I:.-::;:.:.:::::.. ,:.,:::,.:: ,:::::::.:::., :::::., ,::., d: ,::..:.:::::: :::: ..........::::::.:::,.::::.:::::::::..::::,:::.:::: .,:.,.::;:
,::::::.,.::.,.,:::::.:::: ,::.,::::::::I ,::,..:::.,::.,::::::::..:.,.::,::. .:::::::.
::::::: .:.,.,:::::::::::,:::: I:::::::::::::::::::::::::: ::::!::::. I.......... :::.::::::::::::;::.:;::,::::
:::::::::.::::::.::...,.,:::::::::::::::.,::::::::::::..: :::::::::.:::.:-...::.: :::::::::::..: ::::::::::..
,::::::: ,.I I::::.:::..I:::.:.: ..:.:::::::::::..::::::.::::.: .::. :-
:::::::,.:.:::::." ::::,:::.::::.,::::.,:::::: ::::.,:,::: :.::::::::;::,.:;::::,:::..::,:.:.,.:.,,::. ::,..::,
,::::::::::::::,:::::::,:::" :,..:::::::::::::::::::::, :::::;:.-.:.-::.---:::::::::::-.::.................
.:.
...... ::::.,:::
:::::::::::. ,::::::.,::::::::. ,::.::::::::: 1: I::::::;::::::::::::::::::,-:: :::::I.::..:..,:.: d::::::::::::::. :::::::::::.,::::::::::::..:.,::::,:::::: ............................. :::.:.:: .::::.,::
is ............d....... -- ......................d...... :I:::::::::::..:,.::.::: ::::::.':.:'II,IIIIIII ... .-::...... :::::::::::::::.I:: d:::::::: ,::...;.:::..:...:::::. .:..:.
....................::: :::::: 1: ,:::::::::, :::: ,:::.: ......:::!
:.,:::::::.:. ,:::.,:. d:.I::::::::::::::.:::.I.::::: ,:: .,:::,::: .:::::::,::.:.:
::. le:::: :.::.,:: :.::.I..::::::::::::::;::: .,::::::::: :I::::::::::::I..:::::::: !:::.,:::
,::.::., ,:::::.: :::::::::::.:::.,.Id::::::: In ::::::,::.,:::::. .:::. ::::..,:: ,:::: ,:.:.::::.,.,::
:::::.::..::: I.,,: ,::::::::::::: .:,:,:::.....:::, I:::.I::::::::.;::.:.I:.::: :::::,:::, 11 ::::: ,:: :::::::: :::. .:::::::.:::;::% .:: .::. :..::.,:
:::::::::::::::::;::.: ,:::::::: .. .11.1::.::I.: :,:::::: :::.:::: :::::::::::.I::::::::::::., :::::::::,. I%.: :::::::::..
...
:::::.I:I:.I:::::::::.::.I ,:::::.. I... d................. ?......
::,::..,.::::::" :::.,::.::::,:::: .:::::::: :I::::I:.:::;.::.:::::II:
::.:,: :::::::, ::: :::: d........ ::::::U :::::::: ::::::::
10 ::::-:.-.-::.;.::::::::.,::.:::::::::::: :::: 1:
.......... -:1 ::::; ;. :.,:::::: ,::::" ....:...
:.:.,: I..::: :...... -::::: ::.",::,. :.:.:,::: :::::,::
:::::::::::::.:I:,..I ,::::::: ::: .:.,:::::: .;4 :::::.:: ..::::,:. ,::.,:::: ::.,.Id:: ::.:.:.,: ::,::,.,.: :::.:;,.,.
::::::::.I:::.I:.-I:::: :::.,.,::: :::.:.,.,:: ::::.... .........
I:::::::::::.;:..I::: I::;." ::: ........
:::::,.:: ::::,:.: :::::::,. ,..::::: ::.,.,:,:: :::::::: .::::::: ::::::,:: :.,:,:::: :::,...,::
::: :::::::: ::::,::: :::. .:: ::::::,: :::::::.
...... d.. I.... :::::::: :.d
-:::d:l ,:;::.,:: ,::, 11 I :::::.::
. :::::::: ::::,::: ::,::::" .,:. .1
........
5 ::: ,:;:.,:::
,:: ::...:: ::::,::: :::.,:::: :,::::,: :::::::: ........ ::::::::
:.:.::c: :.:,.::.:: :.:!::: .,::::::: :,:::::: :::::::: 11:: ,::::::: :...: ........
::I ;. NII ::,:::::: ,:: 1: :.,::::, .::::::, :::::" .::::::, :,::..
.. :::::.r:: :::.,:::: :: ........ ,::::;:: :::::::, :::::::: :::::::: :,::::.: .,:,::::
:,.':.:
.. ::::::.:
::: ::,::::: ::,:::,.: ::::::.,: :,:::::: :,::.,.,:: ::IX ::. ... ::: :..:::::: ,:::: ::::::.,: ::::dl.l :::.:... ,:.::.,:.d :::::::: ::: :::.
1:1 .... :::::,.: :::::,:: :::::: .:: d... ::::::::
0 1
0 1 1.5 2 2.5 3 3.5 4
Fig. Kurtzke EDSS scores forprevalent patients.
onset (e.g. sphincter disturbance, sexual
dysfunction). Sixty-five patients (22.6%) had a
history of MS among first-, second- or third-
degree relatives.
DISCUSSION
This study was the fourth completed in Northern
Ireland in 50 years. We believe that, given the
resources available, the population size in this
study was optimal for accurate ascertainment of
cases, not so small as to be subject to the quirks
ofclustering andnot solarge as to omitprevalent
cases. Thefirsttwoprevious studies involvedthe
entire population ofthe province 28,29and as such
maybebiasedbyincompleteascertainment, while
the third involved a rather smaller population.30
The rising prevalence seen in the previous three
has been emphasised.
The confidence intervals for the recent study lie
entirely outside those ofthe previous studies, the
differentialbeinggreaterwhenrestrictingtothose
with probable or early probable and latent MS:
1951 - 41/100,000 (95%CI 37-44); 1961 -
57.100,000 (95% CI53-61); 1987 - 104/100,000
(95% CI 85-128), 1996 - 163/100,000 (95% CI
144-185).Thisrisingprevalenceinserialstudies,
although notinvariable,24 has been demonstrated
elsewhere20 and attributed to several factors
including prolonged survival of MS patients,
improvedrecognitionofcases,changesinsurvey
methodology and the widening application of
paraclinical tests in diagnosis. The prevalence
rates for the Ballymena area, being similar to
those for the more recently surveyed Coleraine,
Ballymoney and Moyle districts, encourage our
belief that the methods of case ascertainment
have been thorough and evenly applied.
In the British Isles only Shetland, Orkney and
Suffolk 38 have had higher prevalence rates. All
oftheseinvolvedsignificantlysmallerpopulations
with wide confidence limits and in Suffolk there
was no neurological review. Other similarly
populous areas studied in the British Isles
(Sutton;39pop 169,600: Jersey&Guernsey,21 pop
145,246)havehadsignificantlylowerprevalence
rates. Although there is now little evidence for a
latitudinal gradient within these islands, our
figures, taken together with those in Scotland,
appeartosupporttheexistenceofa"step"between
Northern Ireland/Scotland and England/Wales.
Thisinturnmayreflectthedistinctprofiles ofthe
population bases, the genetic composition and
ethnic origin being similar in Scotland and
Northern Ireland.40
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Overall, this studyreinforced Northern Ireland's
globalposition as ahighprevalence areaforMS.
On the basis of these figures and, with the
presumptionthattheremaybeanevendistribution
ofthe disease across Northern Ireland, we could
extrapolate that almost 3,000 individuals have
definite or probable MS and there are a further
400 suspected cases in the region as a whole. A
comparison ofstandardisedprevalence rates for
probable and definite MS in the UK, that is
prevalence calculated on the basis of the 1961
censuspopulationofNorthernIreland,29is shown
in Table II. The list is limited to those studies
providing sufficient information for such a
comparison to be made.
In light ofthe new and costly disease modifying
therapies becoming available forthe disease 42-43
and the standards being established for the
management of many of its symptoms, these
figures have major implications for health care
provision andthedistribution ofresources toand
withinthehealthserviceinNorthernIreland. The
long and unacceptable delay identified in our
recent study between onset of symptoms and
diagnosis of MS (6.2yrs) partially reflects the
long waiting lists for clinical assessment and
prolonged waiting times for supportive
investigations. Again, given that the newer
disease-modifying agents may be at their most
effective early in the course of the disease, the
imperatives for adequate funding and provision
ofneurological services in Northern Ireland are
clear.
FUTURE STUDY
In order to broaden the awareness ofMS beyond
the intensively surveyed north-east of Northem
Ireland and improve patient access to diagnosis,
treatment and supportive care, we now wish to
establishanMSdatabaseforthewholeofNorthern
Ireland. Thistaskwillemploy similarmethodsto
those outlined in the 1996 prevalence study and
will involve every hospital and general practice.
The recent study detailed here indicates that we
can depend on their support and encouragement.
In addition, continuing investigation of the
immunogenetic predisposing factors within this
stable andhomogeneous population is indicated;
thereremains aneedforupdatedprevalence data
in the Republic of Ireland, based on current
diagnosticcriteriaandemploying morethorough
and now well established means of case
ascertainment.
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TABLE II
Standardisedprevalence rates (SPR)forprobable and definite MS in the UK (based on 1961
Northern Ireland censuspopulation)
Survey Male Female
Population SPR/105 Population SPRI1JO
N. Ireland 199635 74,000 100 77,000 226
Tayside 199627 190,715 85 204,885 236
Jersey 199121 40,620 46 43,462 140
Guernsey 199121 29,836 37 31,328 98
Sussex 199122 289,129 58 307,214 142
S. Cambs 19904' 143,252 66 152,816 171
Rochdale 198925 98,978 75 104,365 156
SEWales 198537 191,302 73 203,044 142
Sutton 198539 81,518 64 89,483 137
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